Get the Stockscreener App
4.00
2.44%
-0.10
Pre-market:
4.04
0.04
+1.00%
Verastem Inc stock is traded at $4.00, with a volume of 2.31M.
It is down -2.44% in the last 24 hours and down -7.41% over the past month.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
See More
Previous Close:
$4.10
Open:
$4.16
24h Volume:
2.31M
Relative Volume:
1.01
Market Cap:
$351.49M
Revenue:
$30.91M
Net Income/Loss:
$-209.47M
P/E Ratio:
-1.202
EPS:
-3.3279
Net Cash Flow:
$-147.13M
1W Performance:
+8.99%
1M Performance:
-7.41%
6M Performance:
-56.85%
1Y Performance:
-28.57%
1-Day Range:
$3.93
$4.19
1-Week Range:
$3.55
$4.19
52-Week Range:
$3.55
$11.24
Verastem Inc Stock (VSTM) Company Profile
Name
Verastem Inc
Sector
Industry
Phone
(781) 292-4200
Address
117 KENDRICK STREET, NEEDHAM, MA
Compare VSTM vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
4.00 | 351.49M | 30.91M | -209.47M | -147.13M | -3.3279 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| Feb-04-26 | Initiated | H.C. Wainwright | Buy |
| Oct-16-25 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-10-25 | Initiated | Jefferies | Buy |
| Mar-24-25 | Reiterated | H.C. Wainwright | Buy |
| Dec-31-24 | Reiterated | BTIG Research | Buy |
| Sep-30-24 | Initiated | Guggenheim | Buy |
| Nov-21-23 | Resumed | BTIG Research | Buy |
| Sep-27-23 | Initiated | B. Riley Securities | Buy |
| Jun-15-23 | Upgrade | Mizuho | Neutral → Buy |
| Sep-07-22 | Resumed | Alliance Global Partners | Buy |
| Apr-29-22 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-14-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-09-22 | Initiated | Truist | Buy |
| Jul-01-21 | Initiated | Alliance Global Partners | Buy |
| May-24-21 | Upgrade | BTIG Research | Neutral → Buy |
| Jun-20-19 | Downgrade | BTIG Research | Buy → Neutral |
| May-10-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-13-18 | Initiated | BTIG Research | Buy |
| May-02-18 | Initiated | Seaport Global Securities | Buy |
| Mar-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-07-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-17 | Initiated | Oppenheimer | Outperform |
| Mar-24-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-29-15 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| Sep-29-15 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-29-15 | Downgrade | Jefferies | Buy → Hold |
| Sep-29-15 | Downgrade | Raymond James | Strong Buy → Outperform |
| Sep-28-15 | Downgrade | Mizuho | Buy → Neutral |
| Sep-28-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-09-15 | Initiated | Raymond James | Strong Buy |
| May-12-15 | Reiterated | UBS | Buy |
| Apr-08-15 | Initiated | H.C. Wainwright | Buy |
| Jan-23-15 | Reiterated | ROTH Capital | Buy |
| Jul-08-14 | Resumed | Oppenheimer | Perform |
| Feb-11-14 | Initiated | Mizuho | Buy |
View All
Verastem Inc Stock (VSTM) Latest News
Early data on new KRAS cancer pill to be detailed June 23 - Stock Titan
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), Jazz Pharmaceuticals (JAZZ) and Humana (HUM) - The Globe and Mail
Why Did Verastem Stock Jump After-Hours Despite An Earnings Miss? - Stocktwits
VSTM Technical Analysis & Stock Price Forecast - Intellectia AI
Verastem’s VS-7375 receives FDA fast track status for lung cancer - Investing.com UK
Verastem announces FDA Fast Track designation for VS-7375 - TipRanks
Verastem, Inc. receives U.S. FDA fast track for KRAS G12D inhibitor in NSCLC treatment - Traders Union
Verastem (VSTM) Surges 11% Following FDA Fast Track Designation - GuruFocus
Verastem’s VS-7375 receives FDA fast track status for lung cancer By Investing.com - Investing.com South Africa
Verastem (VSTM) Receives Fast Track Designation for Cancer Treat - GuruFocus
Verastem stock rises on FDA fast track for lung cancer drug - Investing.com Canada
Verastem Initiates Phase 2 Target-D 202 Trial For Advanced NSCLC - TradingView
Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung - Business Wire
Verastem Inc stock (US92335V1008): Nasdaq-listed oncology player steadies around late-May levels - AD HOC NEWS
VSTM Stock Price, Quote & Chart | VERASTEM INC (NASDAQ:VSTM) - ChartMill
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Verastem (VSTM) Declines 2.5% as Biotech Sector Headwinds PersistPullback Trade - thelegaladvocate.com
Verastem (NASDAQ: VSTM) director receives 108,000 restricted stock units - Stock Titan
New Verastem (NASDAQ: VSTM) director files initial Form 3 ownership - Stock Titan
[144] Verastem, Inc. SEC Filing - Stock Titan
Biopharma Verastem Oncology joins Jefferies healthcare fireside chat June 3 - Stock Titan
Verastem Oncology to Present at Jefferies Healthcare Conference - marketscreener.com
Verastem: Robert Gagnon Stepped Down From Board Following End of Term on May 21 >VSTM - Moomoo
H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Director at Verastem (VSTM) receives 36,000 RSUs as equity award - Stock Titan
Director Brian Stuglik (VSTM) awarded 36,000 Verastem RSUs with 2026–2027 vesting - Stock Titan
Verastem (NASDAQ: VSTM) awards 36,000 RSUs to director Rowinsky - Stock Titan
Verastem (VSTM) director Michelle Robertson awarded 36,000 RSUs - Stock Titan
Verastem (VSTM) director Anil Kapur receives 36,000 RSU equity award - Stock Titan
Verastem (VSTM) director awarded 36,000 RSUs vesting through 2027 - Stock Titan
Verastem (VSTM) director gets 36,000 RSU award vesting through 2027 - Stock Titan
Verastem Oncology Appoints Michael P. Bailey to Board of Directo - GuruFocus
Verastem (VSTM) stockholders back board slate, equity plans and auditor at 2026 meeting - Stock Titan
Verastem Oncology appoints Michael Bailey to board By Investing.com - Investing.com Australia
Verastem Oncology appoints Michael Bailey to board - Investing.com
AVEO CEO Michael Bailey joins Verastem board, rare cancer focus - Stock Titan
Verastem Q1 2026 Earnings: Narrower-than-Expected Loss Beats Estimates; Stock Edges HigherEnergy Earnings Report - thelegaladvocate.com
Verastem (VSTM) Q1 2026 Earnings: Why the Beat MattersEarnings Seasonality - thelegaladvocate.com
Verastem Q1 earnings call highlights - MSN
Verastem Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Cancer Stocks That Are Advancing the Future of Oncology Care - TradingView
Verastem (VSTM) Loses 34.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Verastem Q3 2025 Earnings Preview - MSN
Foresite (VSTM) holds 3,146,631 shares, reporting 3.6% stake - Stock Titan
Armistice Capital 5.23% stake in Verastem (VSTM) via managed fund - Stock Titan
RTW Funds, Roderick Wong Report 9.99% of Verastem (VSTM) - Stock Titan
Balyasny-affiliated holders report 1.36M shares in Verastem (VSTM) - Stock Titan
Verastem Oncology announces management changes - MSN
VSTM Maintained by Mizuho -- Price Target Lowered to $14.00 - GuruFocus
MSN Money - MSN
Mizuho Adjusts Price Target on Verastem to $14 From $16, Maintains Outperform Rating - Moomoo
Verastem Inc Stock (VSTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):